Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside
I'm LongbridgeAI, I can summarize articles.Arcus Biosciences, Inc. stock's average 12-month price target has been raised to $38.82 by 11 analysts, up from $38.33. Based on the August 13 closing price, this implies a 35% upside potential. The consensus rating remains 'Buy' across the 12 covering analysts, comprising 9 Buys and 3 Holds.
- According to estimates from 11 analysts, Arcus Biosciences, Inc. stock's average price target has risen from $38.33 to $38.82, with forecasts ranging from $23 to $47 per share
- Based on the Aug. 13 closing price, the updated target implies approximately 35% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 9 Buys, 3 Holds and 0 Sells
Explore more price target data and ratings for Arcus Biosciences, Inc. on the , and track all previous and future analyst recommendations for Arcus Biosciences, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.